We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allergan (AGN) Collaborates with Novartis to Treat NASH
Read MoreHide Full Article
Allergan plc entered into a collaboration with Novartis AG (NVS - Free Report) to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc (CVC) and Novartis lead Fxr agonist to treat non-alcoholic steatohepatitis (NASH).
A look at Allergan’s year-to-date share price movement shows that the company has outperformed the Zacks classified Medical – Generic Drugs industry. Specifically, the stock gained 11.6% so far this year against a 3.4% decline for the industry.
NASH is the progressive form of non-alcoholic fatty liver disease (NAFLD), which occurs when the accumulation of liver fat is accompanied by inflammation and cellular damage. The inflammation can cause fibrosis of the liver and eventually lead to many complications. Allergan is developing CVC as a once-daily orally administered immunomodulator that blocks chemokine receptors in inflammatory and fibrogenic pathways.
Other than CVC, it is developing evogliptin and AGN-242266 programs, targeting different mechanisms for the treatment of this multi-factorial NASH disease.
With no treatments currently approved for this disease, the market opportunity is significant. With Intercept Pharmaceuticals, Inc.’s Ocaliva, Conatus Pharmaceuticals Inc.’s emricasan and Galmed Pharmaceuticals’s Aramchol, several companies are working on developing treatments for NASH.
In a separate press release, a generic drug company Argentum Pharmaceuticals LLC, which was engaged in a patent dispute over Allergan’s eye drug, Restasis, announced that it has reached a settlement. The agreement grants Argentum the right to market a generic version of Restasis before the expiry of the patent. The drug was approved by the FDA in 2002 to treat dry eye.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Allergan (AGN) Collaborates with Novartis to Treat NASH
Allergan plc entered into a collaboration with Novartis AG (NVS - Free Report) to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc (CVC) and Novartis lead Fxr agonist to treat non-alcoholic steatohepatitis (NASH).
A look at Allergan’s year-to-date share price movement shows that the company has outperformed the Zacks classified Medical – Generic Drugs industry. Specifically, the stock gained 11.6% so far this year against a 3.4% decline for the industry.
NASH is the progressive form of non-alcoholic fatty liver disease (NAFLD), which occurs when the accumulation of liver fat is accompanied by inflammation and cellular damage. The inflammation can cause fibrosis of the liver and eventually lead to many complications. Allergan is developing CVC as a once-daily orally administered immunomodulator that blocks chemokine receptors in inflammatory and fibrogenic pathways.
Other than CVC, it is developing evogliptin and AGN-242266 programs, targeting different mechanisms for the treatment of this multi-factorial NASH disease.
With no treatments currently approved for this disease, the market opportunity is significant. With Intercept Pharmaceuticals, Inc.’s Ocaliva, Conatus Pharmaceuticals Inc.’s emricasan and Galmed Pharmaceuticals’s Aramchol, several companies are working on developing treatments for NASH.
In a separate press release, a generic drug company Argentum Pharmaceuticals LLC, which was engaged in a patent dispute over Allergan’s eye drug, Restasis, announced that it has reached a settlement. The agreement grants Argentum the right to market a generic version of Restasis before the expiry of the patent. The drug was approved by the FDA in 2002 to treat dry eye.
Currently, Allergan carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>